Researchers from Excellamol Inc. presented the design and preclinical characterization of XM161-SN38, a novel IL-13Rα2-targeting polypeptide-drug conjugate being evaluated for the treatment of gliomas.
With the aim of developing an effective and more tolerable conditioning for hematopoietic stem cell transplantation (HSCT), researchers from Molecular Partners AG applied the proprietary ankyrin repeat protein (DARPin) platform to generate a novel multi-specific Switch-DARPin candidate, MP-0621.
Researchers from Bright Minds Biosciences Inc. presented data on the mechanism of action of BMB-101, a novel scaffold 5-HT2C Gq-protein biased designed to treat drug-resistant neurological disorders.
Agios Pharmaceuticals Inc. is learning the hard way the downside of having a pipeline in a product. When a side effect crops up, investors are likely to worry that it may affect the potential of the drug in the numerous diseases the drug could potentially treat.
Researchers have described the development of a novel murine model of glioblastoma established with a patient-derived xenograft (PDX) in humanized mice that harbored an almost complete human immune microenvironment.
Researchers from Janssen Research & Development LLC presented preclinical data for JNJ-87801493, a first-in-class CD20 targeted CD28 costimulatory bispecific antibody (Ab), currently in early clinical development for the treatment of B-cell malignancies.
Researchers from E-Therapeutics plc presented preclinical data for ETX-312, a GalNAc-conjugated short interfering RNA (siRNA), produced using the Galomic platform and being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Glioblastomas (GBMs) are the most malignant brain tumors and remain uncurable. Even after therapy, some glioblastoma stem cells (GSCs) survive in the brain parenchyma and cause tumor recurrence.
RSS
